Black men are disproportionately affected by prostate cancer, including higher rates of diagnosis and mortality. Health equity focuses on removing barriers to screening, diagnosis, treatment, and support so every patient has the opportunity to achieve the best possible outcome.
1 in 6 Black men will develop prostate cancer in their lifetime, compared with about 1 in 8 men overall.1,2
Black men are twice as likely to die from prostate cancer compared with White men.3
Black men are often diagnosed at a younger age and more likely diagnosed with advanced-stage disease.4
Patient Videos
Clinician Insights and Resources
Expert Perspective
Learn why earlier PSA screening may be recommended for Black men and how individual risk factors, family history, and health equity can influence prostate cancer detection and outcomes.
Health Equity
Black men face a higher risk of prostate cancer and are more likely to be diagnosed at a younger age. Guidelines recommend considering earlier PSA screening, often between ages 40 and 45. Patients should discuss when to begin screening with their healthcare provider based on individual risk factors and preferences.
Learn MoreExpert Perspective
Learn how inherited and tumor-based genetic testing can help inform prostate cancer risk, treatment decisions, and family counseling.
References
1. Saka AH, Giaquinto AN, McCullough LE, Tossas KY, Star J, Jemal A, Siegel RL. Cancer statistics for African American and Black people, 2025. CA: A Cancer Journal for Clinicians. 2025;75(2):106-132. doi:10.3322/caac.21874.
2. American Cancer Society: Cancer Facts and Figures 2025. American Cancer Society, 2025. Available online. Accessed August 12, 2026.
3. Centers for Disease Control and Prevention. Cancer and African American People. CDC Cancer and Health Equity. U.S. Department of Health and Human Services. Accessed June 23, 2026. Veterans Health Library. Last annual review date: February 1, 2026. Accessed June 16, 2026.
4. Lillard JW Jr, Moses KA, Mahal BA, George DJ. Racial disparities in Black men with prostate cancer: A literature review. Cancer. 2023;129(1):16-28. doi:10.1002/cncr.34433. PMID: 36066378. PMCID: PMC9826514.
